United Kingdom Renal Denervation Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Symplicity, Enlightn, Vassix, Paradise, Iberis, and Others), By Technology (Radiofrequency, Ultrasound, and Micro-Infusion), By End User (Hospitals, Specialty Clinics, and Others), and United Kingdom Renal Denervation Market Insights, Industry Trend, Forecasts to 2033

United Kingdom Renal Denervation Market Insights Forecasts to 2033

• The U.K. Renal Denervation Market Size is Growing at a CAGR of XX% from 2023 to 2033
• The U.K. Renal Denervation Market Size is Expected to hold a significant share by 2033

The United Kingdom Renal Denervation Market Size is anticipated to hold a significant share by 2033, Growing at a CAGR of XX% from 2023 to 2033. The growing number of hypertension patients, as well as the prevalence of cardiovascular and heart diseases, are driving the growth of the renal denervation market in the UK.     

Market Overview

The renal denervation market is the industry of devices and procedures used for treating resistant hypertension through renal denervation. Renal denervation (RDN) is a minimally invasive procedure used for treating hypertension, specifically resistant hypertension, which doesn’t respond to medications. The prevalence of hypertension and demand for minimally invasive procedures, as well as the development of innovative technologies and improved device performance, are significantly driving the renal denervation market. There is an increasing development of catheter-based interventional therapy that facilitates the denervation of particular nerves and seems to be safer for patients. Advancements in the medical device supportive of the renal denervation procedures are fueling the market growth. The prevalence of therapy-resistant hypertension, as well as growing research & development activities across healthcare, are escalating the market opportunity for renal denervation.

Report Coverage

This research report categorizes the market for the UK renal denervation market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom renal denervation market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the UK renal denervation market.

Driving Factors

The growing number of hypertension patients is responsible for driving the market demand. As per the data by NHS England Digital, 30% of adults had hypertension (high blood pressure), including 15% with untreated hypertension. The concerns about the increasing death rate due to cardiovascular and heart diseases are driving demand for renal denervation for managing cardiovascular and heart diseases, which ultimately propels the market growth. The rising investment towards the introduction of catheter-based renal denervation products in healthcare facilities is promoting the market growth.

 Restraining Factors

The increased procedural cost of renal denervation and alternative treatment options, such as medication and lifestyle changes, are challenging the market. Further, the shortage of skilled medical professionals and the lack of standardization are responsible for restraining the market.

Market Segmentation

The United Kingdom renal denervation market share is classified into product type, technology, and end user. 

• The symplicity segment dominated the market with the largest market share in 2023 and is expected to grow at a significant CAGR during the projected period.

The United Kingdom renal denervation market is segmented by product type into symplicity, enlightn, vassix, paradise, iberis, and others. Among these, the symplicity segment dominated the market with the largest market share in 2023 and is expected to grow at a significant CAGR during the projected period. Symplicity renal denervation procedure uses radiofrequency energy for reducing blood pressure by disrupting overactive sympathetic signals between the kidneys and brain. The low level radiofrequency energy and reduced radiation risk on body tissues by the symplicity system is driving the market. 

• The radiofrequency segment dominated the market with the largest market share and is expected to grow at a significant CAGR during the projected period.

The United Kingdom renal denervation market is segmented by technology into radiofrequency, ultrasound, and micro-infusion. Among these, the radiofrequency segment dominated the market with the largest market share and is expected to grow at a significant CAGR during the projected period. Radiofrequency pulses are applied, burning the nerves in the walls of the renal arteries during the RDN procedure. The increased use of radiofrequency renal denervation for effectively controlling resistant hypertension is propelling the market in the radiofrequency segment.

• The hospitals segment dominated the United Kingdom renal denervation market and is expected to grow at a significant CAGR during the projected period.

The United Kingdom renal denervation market is segmented by end user into hospitals, specialty clinics, and others. Among these, the hospitals segment dominated the United Kingdom renal denervation market and is expected to grow at a significant CAGR during the projected period. Hospitals are key end-users of renal denervation devices and procedures for treating resistant hypertension. The rising prevalence of hypertension is driving demand for renal denervation procedures, thereby propelling market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the U.K. renal denervation market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Medtronic United Kingdom
• Boston Scientific Limited
• Abbott Laboratories Limited
• CardioSonic Limited
• Terumo UK Limited
• Johnson & Johnson Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In November 2023, the FDA approved a second renal denervation device to treat adults with uncontrolled hypertension despite an advisory panel’s vote regarding that system’s risks and benefits, Medtronic announced.

Market Segment

This study forecasts revenue at U.K., regional, and country levels from 2020 to 2033. Spherical Insights has segmented the United Kingdom Renal Denervation Market based on the below-mentioned segments:

UK Renal Denervation Market, By Product Type

• Symplicity
• Enlightn
• Vassix
• Paradise
• Iberis
• Others

UK Renal Denervation Market, By Technology  

• Radiofrequency
• Ultrasound
• Micro-Infusion

UK Renal Denervation Market, By End User

• Hospitals
• Specialty Clinics
• Others